Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon

J Acquir Immune Defic Syndr. 2006 Jun;42(2):135-9. doi: 10.1097/01.qai.0000223017.01568.e7.

Abstract

An effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-mediated immune (CMI) responses against divergent HIV-1 clades. We compared anti-HIV-1 T-cell immune responses among 363 unvaccinated adults infected with diverse HIV-1 clades. Response rates to clade B Gag and/or clade B Nef in Botswana (95%) and Cameroon (98%) were similar when compared with those in countries previously studied, including Brazil (92%), Thailand (96%), South Africa (96%), Malawi (100%), and the United States (100%). Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Botswana
  • Cameroon
  • Cells, Cultured
  • Female
  • Gene Products, gag / immunology
  • Gene Products, nef / immunology
  • HIV Antigens / immunology*
  • HIV Infections / immunology*
  • HIV-1 / immunology*
  • Humans
  • Interferon-gamma / biosynthesis
  • Leukocytes, Mononuclear / immunology
  • Male
  • Middle Aged
  • T-Cell Antigen Receptor Specificity*
  • T-Lymphocytes / immunology*
  • nef Gene Products, Human Immunodeficiency Virus

Substances

  • Gene Products, gag
  • Gene Products, nef
  • HIV Antigens
  • nef Gene Products, Human Immunodeficiency Virus
  • Interferon-gamma